Overview

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Status:
Unknown status
Trial end date:
2018-06-30
Target enrollment:
0
Participant gender:
All
Summary
Several observational studies have shown improvement in episodic migraine with the use of greater occipital nerve block as an acute therapy, and a recent placebo controlled trial did not show a decrease in frequency of episodic or chronic migraine; however, there has never been a placebo controlled trial to investigate the efficacy of GONB as an acute treatment for headache, and there has been no determination of guidelines for selection of patients who would be most likely to respond to GONB. In light of the above, the investigators propose a double-blind, placebo-controlled, randomized trial examining the use of GONB with lidocaine/bupivocaine in patients with an acute episodic migraine. The results of this trial are expected to guide more appropriate therapeutic management of these participants and the optimal use of this procedure. 50 subjects will be entered into this study. This study is being conducted at Thomas Jefferson University only.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Thomas Jefferson University
Treatments:
Bupivacaine
Lidocaine
Criteria
Inclusion Criteria:

- between the ages of 18 and 80 years old (inclusive) with a previous diagnosis
fulfilling the international classification of headache disorders (ICHD3b) criteria
for episodic migraine, presenting to clinic with an acute episodic migraine reported
as at least a moderate pain level not lasting longer than 7 days at the time of
injection.

Exclusion Criteria:

- subjects who have received greater occipital nerve block (GONB) in the past, subjects
who in their own or the investigator's opinion are unable to describe their symptoms,
subjects who have are scheduled to receive injection of onabotulinum toxin A within 72
hours, subjects who are pregnant or lactating.